Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Long-term exposure to fine particulate matter is associated with a reduced quality of life and lung function in idiopathic ...

Rein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a ...

The therapy showed a ‘favourable’ safety profile both as a single agent and in combination with standard-of-care treatment.

Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...

Over a video call, Alex Zhavoronkov holds up a small, green, diamond-shaped pill. It has been developed by his company to ...

Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to medicines for most patients in the United States—steer patients to use their ...

Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to ...

Idiopathic pulmonary fibrosis is a devastating interstitial lung disease that leads to impaired quality of life and shortened survival. Currently, it has no effective medical therapy. Recent ...

Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report) and increased the price ...

Shares of PureTech Health plc (NASDAQ:PRTC – Get Free Report) were down 6.3% on Thursday . The stock traded as low as $17.04 and last traded at $17.55. Approximately 6,778 shares traded hands during ...